ArticleInternational journal of clinical and experimental medicine2014
Expression and prognostic value of estrogen receptor beta in breast cancer patients.
Article in International journal of clinical and experimental medicine, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed, 1 synthesis or guideline pooled it, 12 citations in OpenAlex.
- Estrogen receptor beta as a prognostic factor in breast cancer patients: A systematic review and meta-analysis.Oncotarget · 2016Pooled it
- Prognostic relevance of RIP140 and ERβ expression in unifocal versus multifocal breast cancers: a preliminary report.International journal of molecular sciences · 2019Article
- The anticancer activity of genistein is increased in estrogen receptor beta 1-positive breast cancer cells.OncoTargets and therapy · 2018Article
- Comprehensive assessment of estrogen receptor beta antibodies in cancer cell line models and tissue reveals critical limitations in reagent specificity.Molecular and cellular endocrinology · 2017Article
- Estrogen receptor beta impacts hormone-induced alternative mRNA splicing in breast cancer cells.BMC genomics · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This study is to determine the expression of estrogen receptor beta (ERβ) in breast cancer patients and to evaluate its relationship with clinicopathological parameters of breast cancer and its effects on the prognosis of breast cancer patients. Paraffin-embedded primary tumor tissue sections from 490 breast cancer patients were collected consecutively from January 2000 to December 2010. They had complete clinical data and follow-up records. Immunohistochemical staining was conducted to determine ERβ expression. The Kaplan-Meier method was used for survival analysis. Difference in survival was analyzed by the Log-Rank test. The Cox proportional hazard model was performed to evaluate the prognostic value of ERβ expression in breast cancer patients. The ERβ high and over expression rate in 490 breast patients was 22.4% (110/490). ERβ expression was not associated with clinicopathological parameters of breast cancer. The mean survival time in patients with ERβ negative expression, ERβ low expression, ERβ high expression and ERβ over expression was 9.9 years, 9.2 years, 8.6 years and 5.6 years. Statistically, patients with ERβ high and over expression had significantly shorter disease-free survival (DFS) time compared with the patients with ERβ negative and low expression. The Cox multivariate analysis revealed that ERβ high and over expression, the pathologic stages of tumor and chemotherapy were the independent predictors for poor DFS in breast cancer patients. ERβ expression is an independent prognostic factor of breast cancer patients and its high and over expression indicates poor prognosis of breast cancer. There was no correlation between ERβ expression and clinicopathological parameters in breast cancer.
Indexed as
Identifiers
25419426PMC4238481W317834158What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.